The trigeminal retrograde transfer pathway in the treatment of neurodegeneration

Journal of Neuroimmunology

Volumn 209, Issue 1-2, 2009, Pages 139-142

  Kyrkanides, Stephanos ^a,c   Yang, Meixiang ^c   Tallents, Ross H ^c   Miller, Jen nie H ^c   Brouxhon, Sabine M ^b,c   Olschowka, John A ^c  

^a STONY BROOK UNIVERSITY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

hexosaminidase; GM2 gangliosidosis; Mouse, Gene therapy; Sandhoff disease

Indexed keywords

VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CENTRAL NERVOUS SYSTEM; FELINE IMMUNODEFICIENCY VIRUS; GENE THERAPY; GM2 GANGLIOSIDOSIS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LYSOSOME STORAGE DISEASE; MOUSE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RETROGRADE NERVE FIBER TRANSPORT; SANDHOFF DISEASE; SENSORY NERVE; TEMPOROMANDIBULAR JOINT; TRIGEMINAL NERVE;

ANIMALS; AXONAL TRANSPORT; BEHAVIOR, ANIMAL; BETA-HEXOSAMINIDASE BETA CHAIN; DISEASE MODELS, ANIMAL; ENCEPHALITIS; G(M2) GANGLIOSIDE; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNODEFICIENCY VIRUS, FELINE; LYSOSOMAL STORAGE DISEASES, NERVOUS SYSTEM; MICE; MICE, KNOCKOUT; NEURODEGENERATIVE DISEASES; SANDHOFF DISEASE; TREATMENT OUTCOME; TRIGEMINAL NERVE;

EID: 64549099776     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.02.006     Document Type: Article

References (16)

1. Akli S., Guidotti J.-E., Vigne E., Perricaudet M., Sandhoff K., Kahn A., and Poenaru L. Restoration of hexosaminidase A activity in human Tay-Sachs fibriblasts via adenoviral vector mediated gene transfer. Gene Ther. 3 (1996) 769-774
2. Brooks A.I., Stein C.S., Hughes S.M., Heth J., McCray Jr. P.M., Sauter S.L., Johnston J.C., Cory-Slechta D.A., Federoff H.J., and Davidson B.L. Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 6216-6221
3. Cachon-Gonzalez M.B., Wang S.Z., Lynch A., Ziegler R., Cheng S.H., and Cox T.M. Effective gene therapy in an authentic model of Tay-Sachs-related diseases. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 10373-10378
4. Dickson P., McEntee M., Vogler C., Le S., Levy B., Peinovich M., Hanson S., Passage M., and Kakkis E. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol. Genet. Metab. 91 (2007) 61-68
5. Griffey M., Macauley S.L., Ogilvie J.M., and Sands M.S. AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis. Mol. Ther. 12 (2005) 413-421
6. Hemsley K.M., King B., and Hopwood J.J. Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice. Mol. Genet. Metab. 90 (2007) 313-328
7. Kyrkanides S., Kambylafkas P., Miller J.H., and Tallents R.H. Non-primate lentiviral vector administration in the TMJ. J. Dent. Res. 83 (2004) 65-70
8. Kyrkanides S., Miller J.H., Brouxhon S.M., Olschowka J.A., and Federoff H.J. β-hexosaminidase lentiviral vectors: transfer into the CNS via systemic administration. Mol. Brain Res. 133 (2005) 286-298
9. Kyrkanides S., Miller J.H., Tallents R.H., Brouxhon S.M., Centola G., and Olschowka J.A. Intraperitoneal inoculation of Sandhoff mouse neonates with an HIV-1 based lentiviral vector exacerbates the attendant neuroinflammation and disease phenotype. J. Neuroinflam. 188 (2007) 39-47
10. Kyrkanides S., Fiorentino P.M., Miller J.N., Gan Y., Lai Y.C., Shaftel S.S., Puzas J.E., Piancino M.G., O'Banion M.K., and Tallents R.H. Amelioration of pain and histopathologic joint abnormalities in the Col1-IL-1beta(XAT) mouse model of arthritis by intraarticular induction of mu-opioid receptor into the temporomandibular joint. Arthr. Rheum. 56 (2007) 2038-2048
11. -/- mouse model of neurodegeneration. J. Neuroimmunol 203 (2008) 50-57
12. Lacorazza H.D., Flax J.D., Snyder E.Y., and Jendoubi M. Expression of human beta-hexosaminidase alpha-subunit gene (the gene defect of Tay-Sachs disease) in mouse brains upon engraftment of transduced progenitor cells. Nat. Med. 2 (1996) 424-429
13. Olschowka J.A., Bowers W.J., Hurley S.D., Mastrangelo M.A., and Federoff H.J. Helper-free HSV-1 amplicons elicit a markedly less robust innate immune response in the CNS. Molec. Ther. 7 (2003) 218-227
14. Proia R.L., d'Azzo A., and Neufeld E.F. Association of a- and b-subunits during the biosynthesis of b-hexosaminidase in cultured human fibroblasts. J. Biol. Chem. 259 (1984) 3350-3354
15. Sango K., Yamanaka S., Hoffman A., Okuda Y., Grinberg A., Westphal H., McDonald M.P., Crawley J.N., Sandhoff K., Suzuki K., and Proia R.L. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat. Genet. 11 (1995) 170-176
16. Yamanaka S., Johnson M.D., Grinberg A., Westphal H., Crawley J.N., Taniike M., Suzuki K., and Proia R.L. Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 9975-9979